Targeting angiogenesis: A review of angiogenesis inhibitors in the treatment of lung cancer

Lung Cancer

Volumn 42, Issue 2 SUPPL., 2003, Pages 81-91

  Sridhar, Srikala S ^a   Shepherd, Frances A ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; AE 941; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; CELECOXIB; CO 358774; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; INTERFERON; MARISMATAT; MATRIX METALLOPROTEINASE INHIBITOR; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; N ACETYLCOLCHINOL PHOSPHATE; PRINOMASTAT; REBIMASTAT; SEMAXANIB; SQUALAMINE; TANOMASTAT; THALIDOMIDE; UNCLASSIFIED DRUG; VANDETANIB; VATALANIB; ZK 225846; ZK 225847;

ANGIOGENESIS; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; EVALUATION; HUMAN; LUNG CARCINOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0242637170     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00308-8     Document Type: Conference Paper

References (85)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., et al. Cancer statistics, 2001. CA Cancer J. Clin. 51:(1):2001;15-36.
2. Scott P.A., Harris A.L. Current approaches to targeting cancer using antiangiogenesis therapies. Cancer Treat Rev. 20:(4):1994;393-412.
3. Hobson B., Denekamp J. Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br. J. Cancer. 49:(4):1984;405-413.
4. Cox G., Jones J.L., Walker R.A., et al. Angiogenesis and non-small cell lung cancer. Lung Cancer. 27:(2):2000;81-100.
5. Kerbel R.S. Tumor angiogenesis: past, present and the near future. Carcinogenesis. 21:(3):2000;505-515.
6. Hyder S.M., Stancel G.M. Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins. Mol. Endocrinol. 13:(6):1999;806-811.
7. Liekens S., De Clercq E., Neyts J. Angiogenesis: regulators and clinical applications. Biochem. Pharmacol. 61:(3):2001;253-270.
8. Hidalgo M., Eckhardt S.G. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. 93:(3):2001;178-193.
9. Brooks P.C., Silletti S., von Schalscha T.L., et al. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell. 92:(3):1998;391-400.
10. Brooks P.C., Stromblad S., Sanders L.C., et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell. 85:(5):1996;683-693.
11. Shou Y., Hirano T., Gong Y., et al. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br. J. Cancer. 85:(11):2001;1706-1712.
12. Kodate M., Kasai T., Hashimoto H., et al. Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathol. Int. 47:(7):1997;461-469.
13. Karameris A., Panagou P., Tsilalis T., et al. Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas. A molecular and immunohistochemical study. Am. J. Respir. Crit. Care Med. 156:(6):1997;1930-1936.
14. Chambers A.F., Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89:(17):1997;1260-1270.
15. Khokha R., Denhardt D.T. Matrix metalloproteinases and tissue inhibitor of metalloproteinases: a review of their role in tumorigenesis and tissue invasion. Invasion Metastasis. 9:(6):1989;391-405.
16. Michael M., Babic B., Khokha R., et al. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J. Clin. Oncol. 17:(6):1999;1802-1808.
17. Ray J.M., Stetler-Stevenson W.G. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur. Respir. J. 7:(11):1994;2062-2072.
18. Fortunato S.J., Menon R. Screening of novel matrix metalloproteinases (MMPs) in human fetal membranes. J. Assist. Reprod. Genet. 19:(10):2002;483-486.
19. Ylisirnio S., Hoyhtya M., Turpeenniemi-Hujanen T. Serum matrix metalloproteinases-2, -9 and tissue inhibitors of metalloproteinases-1, -2 in lung cancer - TIMP-1 as a prognostic marker. Anticancer Res. 20:(2B):2000;1311-1316.
20. Laack E., Kohler A., Kugler C., et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann. Oncol. 13:(10):2002;1550-1557.
21. Wojtowicz-Praga S.M., Dickson R.B., Hawkins M.J. Matrix metalloproteinase inhibitors. Invest. New Drugs. 15:(1):1997;61-75.
22. Brown P.D., Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann. Oncol. 6:(10):1995;967-974.
23. Bramhall S.R., Hallissey M.T., Whiting J., et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br. J. Cancer. 86:(12):2002;1864-1870.
24. Steward W.P. Marimastat (BB2516): current status of development. Cancer Chemother. Pharmacol. 43(Suppl):1999;S56-S60.
25. Shepherd F.A., Giaccone G., Seymour L., et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the national cancer institute of Canada-clinical trials group and the European organization for research and treatment of cancer. J. Clin. Oncol. 20:(22):2002;4434-4439.
26. Smylie M, Mercier R, Aboulafia D, et al. Phase III Study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer, Proc ASCO 2001;20:307a (abstr 1226).
27. Bissett D, O'Byrne K, von Pawel J, et al. Phase III study of the the matrix metalloproteinase inhibitor prinomastat in combination with gemcitibine and cisplatin in non-small cell lung cancer, Proc ASCO 2002;21:296a (abstr 1183).
28. Naglich J.G., Jure-Kunkel M., Gupta E., et al. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res. 61:(23):2001;8480-8485.
29. Erlichman C., Adjei A.A., Alberts S.R., et al. Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Ann. Oncol. 12:(3):2001;389-395.
30. Falardeau P., Champagne P., Poyet P., et al. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin. Oncol. 28:(6):2001;620-625.
31. Herbst R.S., Hidalgo M., Pierson A.S., et al. Angiogenesis inhibitors in clinical development for lung cancer. Semin. Oncol. 29:(1 Suppl. 4):2002;66-77.
32. Smyth S.S., Patterson C. Tiny dancers: the integrin-growth factor nexus in angiogenic signaling. J. Cell. Biol. 158:(1):2002;17-21.
33. Ikeda E., Achen M.G., Breier G., et al. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J. Biol. Chem. 270:(34):1995;19 761-19 766.
34. Mukhopadhyay D., Tsiokas L., Zhou X.M., et al. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature. 375:(6532):1995;577-581.
35. Levy A.P., Levy N.S., Goldberg M.A. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J. Biol. Chem. 271:(5):1996;2746-2753.
36. Dvorak H.F., Brown L.F., Detmar M., et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146:(5):1995;1029-1039.
37. Nor J.E., Christensen J., Mooney D.J., et al. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am. J. Pathol. 154:(2):1999;375-384.
38. Gordon MS, Talpaz M, Margolin K, et al. Phase I trial of recombinant human monoclonal anti-vascular endothelial growth factor (anti-VEGF MAB) in patients with metastatic cancer, Proc ASCO 1998;18:435a (abstr 1678).
39. Margolin K, Gordon MS, Talpaz M, et al. Phase 1b trial of Intravenous Recombinant Humanized Monoclonal Antibody (Mab) to Vascular Endothelial Growth Factor (rhuMAB VEGF) in combination with chemotherapy (CHrX) in patients with advanced cancer (CA): Pharmacologic and long-term safety data, Proc ASCO 1999 18: 435a (abstr 1678).
40. DeVore R, Fehrenbacher RS, Herbst RS, et al. A randomized Phase II trial comparing rhuMAb VEGF (Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Cell Growth Factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with Stage III/IV NSCLC, Proc ASCO 2000;19:485a (abstr 1896).
41. Reese D, Frohlich M, Bok R, et al. A phase II trial of humanized monoclonal anti-vascular endothelial growth factor antibody (rhuMAb VEGF) in hormone refractory prostate cancer (HRPC), Proc ASCO 1999;18:351a (abstr 1355).
42. Sledge G, Miller K, Novotny W, et al. A Phase II trial of single-agent rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) in patients with relapsed metastatic breast cancer, Proc ASCO 2000;19:3a (abstr 5c).
43. Bergsland E, Hurwitz H, Fehrenbacher L, et al. A randomized Phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer, Proc ASCO 2000;19:242a (abstr 939).
44. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr. Top. Microbiol. Immunol. 237:1999;1-30.
45. Fong T.A., Shawver L.K., Sun L., et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59:(1):1999;99-106.
46. Rosen L, Mulay M, Mayers A, et al. Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies, Proc ASCO 1999;18:161a (abstr 618).
47. Kuenen B.C., Rosen L., Smit E.F., et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitibine, and SU5416 in patients with solid tumors. J. Clin. Oncol. 20:(6):2002;1657-1667.
48. Hurwitz H, Holden SN, Eckhardt SG, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling in patients with solid tumors, Proc ASCO 2002;21:82a (abtr 325).
49. Tolcher AW, O'Leary J, DeBono JS, et al. A phase I and biologic correlative study of an oral endothelial vascular growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632 in patients with advanced solid tumors, Proc ASCO 2002;21:84a (abstr 334).
50. Roberts WG, Jani J, Beebe J, et al. Preclinical development of CP-547,632, a novel VEGFR-2 inhibitor for cancer therapy, Proc ASCO 2002;21: 119a (abstr 473).
51. Li T.S., Kaneda Y., Ueda K., et al. The influence of tumour resection on angiostatin levels and tumour growth - an experimental study in tumour-bearing mice. Eur. J. Cancer. 37:(17):2001;2283-2288.
52. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:(2):1997;277-285.
53. Boehm T., Folkman J., Browder T., et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:(6658):1997;404-407.
54. Herbst R.S., Hess K.R., Tran H.T., et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 20:(18):2002;3792-3803.
55. Tannock I.F., Hill R.P. The basic science of oncology. 3rd ed. 1998;McGraw-Hill.
56. Ezekowitz R.A., Mulliken J.B., Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N. Engl. J. Med. 326:(22):1992;1456- 1463.
57. Vivacqua RJ, Lebedda J, Keogh WA, et al. Phase I/II study of sequential interferon alpha-2b (IFN-alpha2b) and weekly topotecan/vinorelbine in advanced non-small cell lung cancer (NSCLC), Proc ASCO 2002;226b (abstr 2721).
58. Kelly K., Crowley J.J., Bunn P.A. Jr., et al. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J. Clin. Oncol. 13:(12):1995;2924-2930.
59. Jett J.R., Maksymiuk A.W., Su J.Q., et al. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J. Clin. Oncol. 12:(11):1994;2321-2326.
60. Mattson K., Niiranen A., Pyrhonen S., et al. Natural interferon alfa as maintenance therapy for small cell lung cancer. Eur. J. Cancer. 1992;1387-1391.
61. Lebeau B, Delsalmoniere P, Ozenne G, et al. Alpha Interferon as maintenance therapy for small cell lung cancer (SCLC), Proc ASCO 1999;18:475a (abst 1832).
62. D'Amato R.J., Loughnan M.S., Flynn E., et al. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA. 91:(9):1994;4082-4085.
63. Merchant J, Hammes L, Larson M, et al. Pilot and safety trial of Carboplatin, Paclitaxel and Thalidomide in Advanced Non-Small Cell Lung Cancer, Proc ASCO 2000;18:541a (abstr 2130).
64. Lee SM, James LE, Mohammed-Ali V, et al. A phase II study of carboplatin/etoposide with thalidomide in small cell lung cancer (SCLC), Proc ASCO 2002;21:313a (abstr 1251).
65. Pujol J.L., Daures J.P., Riviere A., et al. Etoposide plus cisplatin with or without the combination of 4′-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J. Natl. Cancer Inst. 93:(4):2001;300-308.
66. Quantin X, Jacot W, Bozonnat MC, Ongoing trials in France. Abstracts of the 8th Central European Lung Cancer Conference. September 1-4, MC. Et al., Vienna Austria. Lung Cancer 2002:37 Suppl 1;S1-S57.
67. Sills A.K. Jr., Williams J.I., Tyler B.M., et al. Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res. 58:(13):1998;2784-2792.
68. Patnaik A, Rowinsky E, Thurman A, et al. A phase I and pharmacokinetic (pk) study of the unique angiogenesis inhibitor Squalamine lactate (MSI1256F), Proc ASCO 1999;18:162a (abstr 622).
69. Bhargava P, Trocky N, Marshall J, et al. A phase I safety, tolerance and pharmacokinetic study of rising dose, rising duration continuous infusion MSI-1256F (Squalamine Lactate) in patients with advanced malignancies, Proc ASCO 1999;18:163a (abstr 623).
70. Kalidas M, Hammond L, Patnaik A, et al. A phase I and pharmacokinetic study of the Angiogenesis Inhibitor, Squalamine Lactate (MSI1256-F), Proc ASCO 2000;19: 180a (abtr 698).
71. Schiller JH, Hammond LA, Carbone DP, et al. Phase 2A trial of Squalamine for the treatment of Advanced Non-small Cell Lung Cancer, Proc ASCO 2001;20: 339a (abstr 1353).
72. Altorki NK, Keresztes RS, Port JL, et al. Celecoxib (Celebrex), a selective COX-2 inhibitor, enhances the response to preoperative paclitaxel/carboplatin in early stage non-small cell lung cancer, Proc ASCO 2002;21:26a (abstr 101).
73. Gridelli C., Maione P., Airoma G., et al. Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer. Curr. Med. Chem. 9:(21):2002;1851- 1858.
74. Goto H., Yano S., Zhang H., et al. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. Cancer Res. 62:(13):2002;3711-3715.
75. Gadgeel SM, LoRusso PM, Wozniak AJ, et al. A dose-escalation study of the novel vascular-targeting agent, ZD6126, in patients with solid tumors, Proc ASCO 2002;21:110a (abstr 438).
76. Siemann D.W., Rojiani A.M. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int. J. Radiat. Oncol. Biol. Phys. 53:(1):2002;164-171.
77. Radema SA, Beerepoot LV, Witteveen PO, et al. Clinical evaluation of the novel vascular-targeting agent, ZD6126: assessment of toxicity and surrogate markers of vascular damage, Proc ASCO 2002;21:110a (abstr 439).
78. Kumar C.C., Malkowski M., Yin Z., et al. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Cancer Res. 61:(5):2001;2232-2238.
79. Eskens F, Dumez H, Verweij J, et al. Phase I and Pharmacologic Study of EMD 121974, an alphaV3 and alphaVB5 integrin inhibitor that perturbs tumor angiogenesis, in patients with solid tumors, Proc ASCO 2000;19:206a (abstr 801).
80. Holden SN, Morrow M, O'Bryant C, et al. Correlative biological assays used to guide dose escalation in a phase I study of the antiangiogenic aVB3 and a VB5 integrin antagonist EMD 121974 (EMD), Proc ASCO 2002;21:28a (abstr 110).
81. Ingber D., Fujita T., Kishimoto S., et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature. 348:(6301):1990;555-557.
82. Teicher B.A., Holden S.A., Ara G., et al. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma. Cancer Chemother. Pharmacol. 38:(2):1996;169-177.
83. Teicher B.A., Dupuis N.P., Robinson M.F., et al. Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. Oncol. Res. 7:(5):1995;237-243.
84. Herbst R.S., Takeuchi H., Teicher B.A. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chemother. Pharmacol. 41:(6):1998;497-504.
85. Herbst R.S., Madden T.L., Tran H.T., et al. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J. Clin. Oncol. 20:(22):2002;4440-4447.